Marker Therapeutics, Inc. (MRKR): Revenue
$3.55M
Year ended 2025-12-31
+0.3%
3-year compound annual growth
+50.0%
5-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $3.55M | -46.2% | 2026-03-18, From 2025-01-01 |
| 2024-12-31 | $6.59M | +99.1% | 2026-03-18, From 2024-01-01 |
| 2023-12-31 | $3.31M | -5.8% | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | $3.51M | +183.0% | 2024-03-26, From 2022-01-01 |
| 2021-12-31 | $1.24M | +166.0% | 2023-03-22, From 2021-01-01 |
| 2020-12-31 | $466.8K | +118.9% | 2022-03-17, From 2020-01-01 |
| 2019-12-31 | $213.2K | +3.5% | 2021-03-09, From 2019-01-01 |
| 2018-12-31 | $206.0K | +12.5% | 2020-03-12, From 2018-01-01 |
| 2017-12-31 | $183.1K | n/a | 2019-03-15, From 2017-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | 2025-12-31 | $3.55M | -46.2% |
| Camp4 Therapeutics Corp (CAMP) | 2025-12-31 | $3.50M | +436.5% |
| CervoMed Inc. (CRVO) | 2025-12-31 | $4.01M | -58.9% |
| China Pharma Holdings, Inc. (CPHI) | 2025-12-31 | $4.14M | -8.5% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $3.02M | +71.6% |
| Xenetic Biosciences, Inc. (XBIO) | 2025-12-31 | $2.98M | +19.0% |
| ProPhase Labs, Inc. (PRPH) | 2025-12-31 | $4.34M | -35.8% |
| Upstream Bio, Inc. (UPB) | 2025-12-31 | $2.85M | +20.4% |
| Cartesian Therapeutics, Inc. (RNAC) | 2025-12-31 | $2.80M | -92.8% |
Compare MRKR, CAMP, CRVO, CPHI side by side · Screen every company in Pharmaceutical Preparations ↗